Natural history of multiple myeloma with de novo del(17p)

Arjun Lakshman, Utkarsh Painuly, S Vincent Rajkumar, Rhett P. Ketterling, Prashant Kapoor, Patricia T Greipp, Morie Gertz, Francis K. Buadi, Martha Lacy, David M Dingli, Angela Dispenzieri, Amie L. Fonder, Suzanne R. Hayman, Miriam A. Hobbs, Wilson Gonsalves, Yi Lisa Hwa, Nelson Leung, Ronald S. Go, Yi Lin, Taxiarchis KourelisRahma Warsame, John A. Lust, Stephen J Russell, Steven R. Zeldenrust, Robert A. Kyle, Shaji K Kumar

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We compared the outcomes of 310 patients with newly diagnosed multiple myeloma with del(17p) detected by FISH to patients with high-risk translocations (HRT) (n = 79) and standard-risk (SR) cytogenetics (n = 541). The median progression-free survival (PFS) following initial therapy for the three groups was 21.1, 22, and 30.1 months, respectively (P = 0.437- del(17p) vs. HRT); the median overall survival (OS) was 47.3, 79.1, and 109.8 months, respectively, (P = 0.007- del(17p) vs. HRT). PFS and OS for patients with relative loss of 17p (n = 21) were comparable to other patients with del(17p). The PFS was similar between the del(17p) and HRT groups when stratified for age, ISS stage or treatment. The OS of del(17p) and HRT groups were similar in presence of advanced age, ISS III stage or if patients did not receive a proteasome-inhibitor containing induction. ISS III stage, high LDH and HRT, but not the percentage of cells with del(17p) predicted shorter OS in patients with del(17p). The median OS for low (ISS I, normal LDH and no HRT), intermediate (neither low nor high-risk) and high-risk (ISS III and either elevated LDH or coexistent HRT) groups among del(17p) patients were 96.2, 45.4, and 22.8 months, respectively, allowing further risk stratification.

Original languageEnglish (US)
Article number32
JournalBlood cancer journal
Volume9
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Multiple Myeloma
Survival
Disease-Free Survival
Proteasome Inhibitors
Group Psychotherapy
Cytogenetics

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Natural history of multiple myeloma with de novo del(17p). / Lakshman, Arjun; Painuly, Utkarsh; Rajkumar, S Vincent; Ketterling, Rhett P.; Kapoor, Prashant; Greipp, Patricia T; Gertz, Morie; Buadi, Francis K.; Lacy, Martha; Dingli, David M; Dispenzieri, Angela; Fonder, Amie L.; Hayman, Suzanne R.; Hobbs, Miriam A.; Gonsalves, Wilson; Hwa, Yi Lisa; Leung, Nelson; Go, Ronald S.; Lin, Yi; Kourelis, Taxiarchis; Warsame, Rahma; Lust, John A.; Russell, Stephen J; Zeldenrust, Steven R.; Kyle, Robert A.; Kumar, Shaji K.

In: Blood cancer journal, Vol. 9, No. 3, 32, 01.03.2019.

Research output: Contribution to journalArticle

Lakshman, A, Painuly, U, Rajkumar, SV, Ketterling, RP, Kapoor, P, Greipp, PT, Gertz, M, Buadi, FK, Lacy, M, Dingli, DM, Dispenzieri, A, Fonder, AL, Hayman, SR, Hobbs, MA, Gonsalves, W, Hwa, YL, Leung, N, Go, RS, Lin, Y, Kourelis, T, Warsame, R, Lust, JA, Russell, SJ, Zeldenrust, SR, Kyle, RA & Kumar, SK 2019, 'Natural history of multiple myeloma with de novo del(17p)', Blood cancer journal, vol. 9, no. 3, 32. https://doi.org/10.1038/s41408-019-0191-y
Lakshman, Arjun ; Painuly, Utkarsh ; Rajkumar, S Vincent ; Ketterling, Rhett P. ; Kapoor, Prashant ; Greipp, Patricia T ; Gertz, Morie ; Buadi, Francis K. ; Lacy, Martha ; Dingli, David M ; Dispenzieri, Angela ; Fonder, Amie L. ; Hayman, Suzanne R. ; Hobbs, Miriam A. ; Gonsalves, Wilson ; Hwa, Yi Lisa ; Leung, Nelson ; Go, Ronald S. ; Lin, Yi ; Kourelis, Taxiarchis ; Warsame, Rahma ; Lust, John A. ; Russell, Stephen J ; Zeldenrust, Steven R. ; Kyle, Robert A. ; Kumar, Shaji K. / Natural history of multiple myeloma with de novo del(17p). In: Blood cancer journal. 2019 ; Vol. 9, No. 3.
@article{feef324e95b046e2b25376a58a8aff78,
title = "Natural history of multiple myeloma with de novo del(17p)",
abstract = "We compared the outcomes of 310 patients with newly diagnosed multiple myeloma with del(17p) detected by FISH to patients with high-risk translocations (HRT) (n = 79) and standard-risk (SR) cytogenetics (n = 541). The median progression-free survival (PFS) following initial therapy for the three groups was 21.1, 22, and 30.1 months, respectively (P = 0.437- del(17p) vs. HRT); the median overall survival (OS) was 47.3, 79.1, and 109.8 months, respectively, (P = 0.007- del(17p) vs. HRT). PFS and OS for patients with relative loss of 17p (n = 21) were comparable to other patients with del(17p). The PFS was similar between the del(17p) and HRT groups when stratified for age, ISS stage or treatment. The OS of del(17p) and HRT groups were similar in presence of advanced age, ISS III stage or if patients did not receive a proteasome-inhibitor containing induction. ISS III stage, high LDH and HRT, but not the percentage of cells with del(17p) predicted shorter OS in patients with del(17p). The median OS for low (ISS I, normal LDH and no HRT), intermediate (neither low nor high-risk) and high-risk (ISS III and either elevated LDH or coexistent HRT) groups among del(17p) patients were 96.2, 45.4, and 22.8 months, respectively, allowing further risk stratification.",
author = "Arjun Lakshman and Utkarsh Painuly and Rajkumar, {S Vincent} and Ketterling, {Rhett P.} and Prashant Kapoor and Greipp, {Patricia T} and Morie Gertz and Buadi, {Francis K.} and Martha Lacy and Dingli, {David M} and Angela Dispenzieri and Fonder, {Amie L.} and Hayman, {Suzanne R.} and Hobbs, {Miriam A.} and Wilson Gonsalves and Hwa, {Yi Lisa} and Nelson Leung and Go, {Ronald S.} and Yi Lin and Taxiarchis Kourelis and Rahma Warsame and Lust, {John A.} and Russell, {Stephen J} and Zeldenrust, {Steven R.} and Kyle, {Robert A.} and Kumar, {Shaji K}",
year = "2019",
month = "3",
day = "1",
doi = "10.1038/s41408-019-0191-y",
language = "English (US)",
volume = "9",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Natural history of multiple myeloma with de novo del(17p)

AU - Lakshman, Arjun

AU - Painuly, Utkarsh

AU - Rajkumar, S Vincent

AU - Ketterling, Rhett P.

AU - Kapoor, Prashant

AU - Greipp, Patricia T

AU - Gertz, Morie

AU - Buadi, Francis K.

AU - Lacy, Martha

AU - Dingli, David M

AU - Dispenzieri, Angela

AU - Fonder, Amie L.

AU - Hayman, Suzanne R.

AU - Hobbs, Miriam A.

AU - Gonsalves, Wilson

AU - Hwa, Yi Lisa

AU - Leung, Nelson

AU - Go, Ronald S.

AU - Lin, Yi

AU - Kourelis, Taxiarchis

AU - Warsame, Rahma

AU - Lust, John A.

AU - Russell, Stephen J

AU - Zeldenrust, Steven R.

AU - Kyle, Robert A.

AU - Kumar, Shaji K

PY - 2019/3/1

Y1 - 2019/3/1

N2 - We compared the outcomes of 310 patients with newly diagnosed multiple myeloma with del(17p) detected by FISH to patients with high-risk translocations (HRT) (n = 79) and standard-risk (SR) cytogenetics (n = 541). The median progression-free survival (PFS) following initial therapy for the three groups was 21.1, 22, and 30.1 months, respectively (P = 0.437- del(17p) vs. HRT); the median overall survival (OS) was 47.3, 79.1, and 109.8 months, respectively, (P = 0.007- del(17p) vs. HRT). PFS and OS for patients with relative loss of 17p (n = 21) were comparable to other patients with del(17p). The PFS was similar between the del(17p) and HRT groups when stratified for age, ISS stage or treatment. The OS of del(17p) and HRT groups were similar in presence of advanced age, ISS III stage or if patients did not receive a proteasome-inhibitor containing induction. ISS III stage, high LDH and HRT, but not the percentage of cells with del(17p) predicted shorter OS in patients with del(17p). The median OS for low (ISS I, normal LDH and no HRT), intermediate (neither low nor high-risk) and high-risk (ISS III and either elevated LDH or coexistent HRT) groups among del(17p) patients were 96.2, 45.4, and 22.8 months, respectively, allowing further risk stratification.

AB - We compared the outcomes of 310 patients with newly diagnosed multiple myeloma with del(17p) detected by FISH to patients with high-risk translocations (HRT) (n = 79) and standard-risk (SR) cytogenetics (n = 541). The median progression-free survival (PFS) following initial therapy for the three groups was 21.1, 22, and 30.1 months, respectively (P = 0.437- del(17p) vs. HRT); the median overall survival (OS) was 47.3, 79.1, and 109.8 months, respectively, (P = 0.007- del(17p) vs. HRT). PFS and OS for patients with relative loss of 17p (n = 21) were comparable to other patients with del(17p). The PFS was similar between the del(17p) and HRT groups when stratified for age, ISS stage or treatment. The OS of del(17p) and HRT groups were similar in presence of advanced age, ISS III stage or if patients did not receive a proteasome-inhibitor containing induction. ISS III stage, high LDH and HRT, but not the percentage of cells with del(17p) predicted shorter OS in patients with del(17p). The median OS for low (ISS I, normal LDH and no HRT), intermediate (neither low nor high-risk) and high-risk (ISS III and either elevated LDH or coexistent HRT) groups among del(17p) patients were 96.2, 45.4, and 22.8 months, respectively, allowing further risk stratification.

UR - http://www.scopus.com/inward/record.url?scp=85062584929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062584929&partnerID=8YFLogxK

U2 - 10.1038/s41408-019-0191-y

DO - 10.1038/s41408-019-0191-y

M3 - Article

C2 - 30846679

AN - SCOPUS:85062584929

VL - 9

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 3

M1 - 32

ER -